1. Home
  2. ADVM vs ROMA Comparison

ADVM vs ROMA Comparison

Compare ADVM & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • ROMA
  • Stock Information
  • Founded
  • ADVM 2006
  • ROMA 2018
  • Country
  • ADVM United States
  • ROMA Hong Kong
  • Employees
  • ADVM N/A
  • ROMA N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • ROMA Savings Institutions
  • Sector
  • ADVM Health Care
  • ROMA Finance
  • Exchange
  • ADVM Nasdaq
  • ROMA Nasdaq
  • Market Cap
  • ADVM 47.4M
  • ROMA 50.6M
  • IPO Year
  • ADVM 2014
  • ROMA 2024
  • Fundamental
  • Price
  • ADVM $2.74
  • ROMA $3.35
  • Analyst Decision
  • ADVM Strong Buy
  • ROMA
  • Analyst Count
  • ADVM 5
  • ROMA 0
  • Target Price
  • ADVM $23.80
  • ROMA N/A
  • AVG Volume (30 Days)
  • ADVM 297.2K
  • ROMA 319.8K
  • Earning Date
  • ADVM 08-11-2025
  • ROMA 08-01-2025
  • Dividend Yield
  • ADVM N/A
  • ROMA N/A
  • EPS Growth
  • ADVM N/A
  • ROMA N/A
  • EPS
  • ADVM N/A
  • ROMA N/A
  • Revenue
  • ADVM $1,000,000.00
  • ROMA $1,029,120.00
  • Revenue This Year
  • ADVM N/A
  • ROMA N/A
  • Revenue Next Year
  • ADVM $18.82
  • ROMA N/A
  • P/E Ratio
  • ADVM N/A
  • ROMA N/A
  • Revenue Growth
  • ADVM N/A
  • ROMA N/A
  • 52 Week Low
  • ADVM $1.78
  • ROMA $0.46
  • 52 Week High
  • ADVM $10.14
  • ROMA $4.14
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 59.62
  • ROMA 55.98
  • Support Level
  • ADVM $2.50
  • ROMA $3.23
  • Resistance Level
  • ADVM $2.75
  • ROMA $3.61
  • Average True Range (ATR)
  • ADVM 0.20
  • ROMA 0.27
  • MACD
  • ADVM 0.06
  • ROMA -0.02
  • Stochastic Oscillator
  • ADVM 82.50
  • ROMA 47.78

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for its clients' organizations and the world.

Share on Social Networks: